TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Harmonic Versus Electro Surgery in Lower Body Lift Procedures

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects eligible for this clinical research study must fulfill all of the following criteria:~* Elect to undergo a Lower Body Lift procedure for post-obesity reasons;~* Able to comprehend and sign the study informed consent form;~* Able to return for all study mandated visits;~* Be a male or female greater than or equal to 18 years of age;~* Obtain medical clearance for a Lower Body Lift procedure according to institutional requirements.~Exclusion Criteria:~Subjects with any of the following criteria are not eligible to participate in this clinical research study:~* American Society Anesthesiologists (ASA) Classification of Physical Status greater than III;~* Current smoker (documented abstinence of 3 months);~* Documented current use of steroids or anti-inflammatory medications (within the past month) and no history of prolonged usage (for 1 month in the past 3 months);~* Diabetes mellitus (requiring treatment within the past year);~* Need of concomitant surgical procedures in which the wound drainage would interconnect with the wound regions studied by the trial (with the exception of liposuction);~* Presence of ventral or umbilical hernia requiring repair with the use of prosthetic material (e.g. mesh);~* Morbid obesity (Body Mass Index ≥ 40);~* At risk for ischemia due to presence of obstruction of the arterial blood supply or inadequate blood flow;~* Presence of scars that could limit flap advancement or that could not be completely excised;~* Current diagnosis or history of any disease that would impair the healing process;~* Current diagnosis or history of immune system disorders;~* Documented history of bleeding disorders;~* Presence of uncontrolled hypertension;~* Pregnant or lactating;~* Being treated with anticoagulants including aspirin within 7 days prior to surgery (a washout period of 7 days will be required); or~* Participation in any other clinical studies within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Electro Surgery (Type: None): Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tongue Conservation Surgery for Oral Tongue Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological proof of squamous cell carcinoma of oral tongue~* b. cT2-4, N0-2,M0, by clinical or radiographic examinations~* Either mandibulotomy, mandibulectomy or flap reconstruction is required by standard surgical planning~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Between 20 and 70 years of age~* Adequate hematopoietic function as defined below:~Hemoglobin \>= 10g/dl Absolute neutrophil count (ANC) \>= 1,500/µL Platelets \>= 100,000/µL~* Adequate organ function as defined below:~Total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine \<= 1.5 x upper limit of normal Creatinine clearance \> 50 ml/min~* Signed study-specific consent form prior to study entry~Exclusion Criteria:~* Patients received gross oral tongue tumor resection before evaluation~* Primary subsites other than oral tongue~* Histologic diagnosis other than squamous cell carcinoma~* Patient with synchronous primary cancers (within 6 months)~* Clinical or radiographic findings as below:~T1 tumors Gross invasion to mandible, tonsil or \>1/3 base of tongue N3 disease or distant metastasis (M1)~* Prior head and neck chemotherapy or radiotherapy~* Prior esophageal cancer history~* Active cardiac disease defined as: unstable angina, uncontrolled arrhythmia, myocardial infarction within 6 months.~* Severe chronic obstructive pulmonary disease (COPD) requiring ≥ 3 hospitalizations over the past year~* Mental status not fit for clinical trial.~* Pregnant or breast feeding women, or women of child-bearing potential unless using a reliable and appropriate contraceptive method.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Induction chemotherapy (Type: EXPERIMENTAL): Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with primary or metastatic brain tumor~* able to wear wireless activity tracker~* able to complete QOL and sleep surveys every 3 months~Exclusion Criteria:~* unable to provide consent~* age \< 18~* lack of use of the wireless activity tracker for more than 2 consecutive months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Wireless Activity tracker: Fitbit (Type: None): Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Automated Administration of Fluids Guided by Dynamic Parameters and Cardiac Output During General Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient will receive general anesthesia for a surgical procedure with the following characteristics: ----- planned abdominal surgery by laparotomy or laparoscopy with a probable duration\> 2 hours ----- invasive monitoring of blood pressure ----- administration of crystalloid and colloid (HEA PM \<150 kDa)~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient, or breastfeeding~* The patient has a contraindication for a treatment used in this study: ----- Contraindications to the administration of HES MW \<150 kDa ----- Patient classified NYHA\> 2 ----- Allergy to HEA~* The patient has a pacemaker~* Surgery with cardiopulmonary bypass~* Surgery on the skull~* Dementia~* Patients with brain pathology (tumor, stroke, Parkinson's disease, ...)~* Patients with a psychiatric disorder, severe depression or psychosis, as well as those receiving antipsychotic treatment~* Limitations concerning the use of respiratory pulse pressure variation: cardiac arrhythmia, spontaneous ventilation, using a volume flow \<7 ml / kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- The study population (Type: EXPERIMENTAL): See inclusion/exclusion criteria.~Intervention: LIR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years ≤ Age ≤ 75 years~* PS ECOG 0 or 1~* Histologically proven NSCLC~* Unresectable stage III: T1 or T2 or T3 ≤ 5 cm AND N2 or N3 (only contralateral mediastinum or homolateral supraclavicular).~* Peripheral primary tumor ≥ 1 cm and ≤ 5 cm~* Possible concomitant chemoradiotherapy : 1 cure induction and 3 concomitant cycles of chemotherapy with cisplatin and Navelbine ® and 3D conformal radiotherapy delivering 66 Gy in 33 fractions to the mediastinal lymph node involvement without treating the peripheral tumor.~* Adequate biological parameters~* Forced expiratory volume (FEV) ≥1 liter or ≥ 30% of the theoretical value~* Patient covered by a health insurance scheme~* Signed informed consent~Exclusion Criteria:~* SCLC or large cell neuroendocrine carcinoma~* Metastatic disease~* Stage IVa~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SBRT (Type: EXPERIMENTAL): Study treatment = SBRT for peripheral primary tumor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study of Echocardiogram Accuracy in Patients With Mitral Valve Calcification

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>= 19 years of age~* undergoing planned cardiac catheterization~Exclusion Criteria:~* \< 19 years of age~* acute coronary syndrome~* decompensated heart failure~* not in sinus rhythm~* \> mild MR~* hypertensive urgency/emergency~* severe aortic stenosis~* poor echo windows for Doppler imaging

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mild to Severe MAC (Type: None): None
- No to mild MAC (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients currently treated at the University of Mississippi Medical Center General Internal Medicine/Hypertension or Family Medicine Clinics.~* Have a diagnosis of gout.~* Taking allopurinol at a stable dose for at least 2 months.~Exclusion Criteria:~* Less than 18 years old.~* Severe renal impairment defined as CrCl \<30 mL/min.~* Previous diagnosis of severe hepatic impairment.~* Currently taking azathioprine, mercaptopurine, or theophylline.~* Pregnant, breastfeeding, or anticipating pregnancy or breastfeeding.~* Arm circumference greater than 50 cm.~* Change in antihypertensive medication within the previous 2 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol, febuxostat (Type: EXPERIMENTAL): Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed newly diagnosed squamous cell carcinoma of the head and neck~  * Stage III or IV disease~ * Unresectable disease~* Unidimensionally or bidimensionally measurable disease~* Skin and tumor material must be available for EGFR status and downstream signaling studies~* No nasopharyngeal, nasal, or paranasal cancer~* No distant metastases~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times the upper limit of normal (ULN)~* Alkaline phosphatase and transaminases ≤ 2.5 times ULN~* Serum creatinine ≤ 120 μmol/L (1.36 mg/dL)~* Creatinine clearance ≥ 60 mL/min~* Normal cardiac function (i.e., LVEF ≥ 50%)~* Clinically satisfactory 12-lead ECG~* No serious cardiac illness or medical condition within the past 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No current malignancies at other sites with the exception of cone-biopsied carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma or other cancer from which the patient has been disease-free for at least the past five years~* No unstable systemic diseases~* No active uncontrolled infections~* No psychological, familial, sociological, or geographical condition that would preclude compliance with the study protocol and follow-up schedule~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior treatment for head and neck cancer~* No other concurrent anticancer therapy~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Home Hospital for Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Receiving their lymphoma care with curative intent at MGH (treatment intent based upon chemotherapy order in the electronic medical record)~* Hemodynamically stable during the first 24 hours of hospital admission at MGH~* Residing within the designated geographic area for MGH Home Hospital Service (an approximately 10-mile radius from MGH)~* Able to communicate and respond to questionnaires in English~* Lives with a family member or a friend who supports the patient at home~* Deemed eligible for supportive oncology care at home based on the MGH Home Hospital clinician evaluation~Exclusion Criteria:~* Those admitted to the intensive care unit~* Have high oxygen requirement (FIO2 \> 0.4)~* Experience active angina or cardiac arrythmias~* Have a planned inpatient surgical or interventional procedure~* Have uncontrolled psychiatric illness or impaired cognition that prohibits complying with the study procedures~* Have uncontrolled pain requiring intravenous pain medications~* Those deemed ineligible based on the Home Hospital Service clinician evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Home Hospital for Lymphoma (Type: EXPERIMENTAL): The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Strategies for Fragile Patients With Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 65 years or older~2. Decompensated heart failure~3. FRAIL scale equal to 3 or more points~4. Permanent residence in the Metropolitan Area of Buenos Aires~Exclusion Criteria:~1. Refusal to participate in the study~2. Terminal oncology or cardiological disease~3. Reversible or treatable etiology heart failure (e.g. Takotsubo, acute cardiomyocarditis)~4. Patients followed by geriatrics prior to admission~5. Simultaneous participation in another research protocol

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Management Program (Type: EXPERIMENTAL): Comanagement program (cardiological-geriatric) to carry out during hospitalization a comprehensive evaluation that allows to know the medical and socio-environmental needs of the patients to plan the required care at home and achieve an effective transition.
- Usual Care (Type: NO_INTERVENTION): Usual care during hospitalizacion and discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Continuous Transversus Abdominis Plane (TAP) Catheters on Postoperative Pain After Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is \>18 years of age~* The patient has provided written informed consent and understands the explanation of the protocol.~* The patient is scheduled to have a unilateral renal transplant with a flank incision~Exclusion Criteria:~* Patients aged \<18.~* Patients with a known allergy to amide local anesthetics or para-aminobenzoic acid.~* Patients who are unable to understand the verbal analog pain scale.~* Patients who decline participation.~* Patients with a midline abdominal incision.~* Combined transplants, ie. Kidney-pancreas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Fentanyl IV PCA and placebo TAP catheter (Type: PLACEBO_COMPARATOR): Patients will receive Fentanyl IV PCA and placebo TAP catheter.
- TAP catheter with continuous infusion of Ropivicaine (Type: ACTIVE_COMPARATOR): Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Instability Index: The Impact to Care With a New Predictive Indicator

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the study unit will be invited to participate in the study.~* Study subject has to stay in study unit for at least 12 hours.~Exclusion Criteria:~* Patients who were discharged from study unit earlier then 12 hours after admission.~* Patients who are or become dependent on extracorporeal membrane oxygenation (ECMO) support.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- visible HII - patient assessment (Type: EXPERIMENTAL): Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven (i.e., not borderline) epithelial ovarian carcinoma~* Measurable disease~* Recurrence of disease or disease progression indicative of failure of first-line platinum-based chemotherapy~* Disease-free from prior malignancies for \>5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Adequate renal creatinine (\<2.5 mg/dL (\<220 μmol/L)) \& liver function (aspartate amino transferase (AST) and alanine amino transferase (ALT) \<2 x upper limit of normal, alkaline phosphatase \<2.0 x upper limit of normal, except if attributed to tumor, and bilirubin \< upper limit of normal)~Exclusion Criteria:~* Pregnant or breast feeding~* Life expectancy of \<3 months~* Prior radiation therapy to more than one-third of hematopoietic sites within 30 days prior to first dose of study drug~* Prior therapy with DOXIL or paclitaxel~* Prior chemotherapy within 28 days of first dose of study drug (or 42 days if subject has received a nitrosourea or mitomycin)~* Treated with high dose therapy supported by bone marrow or peripheral stem cell transplantation at any time

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): None
- 002 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues